-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 18, Cylon Pharmaceuticals issued an announcement stating that after the third meeting of the third board of directors, it was agreed that the company would transfer 100% of its wholly-owned subsidiary Hunan Shenglong to the transferee Wu Gulin.
The price was 10.
238 million yuan, and the board of directors authorized the company’s management to handle matters related to this equity transfer
.
The company will sign the "Equity Transfer Agreement" with Wu Gulin
It is understood that this equity transfer is to integrate and optimize the company's resources
.
The equity transfer does not involve personnel placement, nor does it involve other arrangements such as changes in the management personnel of listed companies